×
About 9,043 results

ALLMedicine™ Mesothelioma Center

Research & Reviews  3,250 results

Malignant Mesothelioma Mortality in Women - United States, 1999-2020.
https://doi.org/10.15585/mmwr.mm7119a1
MMWR. Morbidity and Mortality Weekly Report; Mazurek JM, Blackley DJ et. al.

May 14th, 2022 - Inhalation of asbestos fibers can cause malignant mesothelioma, a rapidly progressing and lethal cancer of the mesothelium, the thin layer of tissues surrounding internal organs in the chest and abdomen. Patients with malignant mesothelioma have a...

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04840615

May 13th, 2022 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04158141

May 13th, 2022 - PRIMARY OBJECTIVE: I. To detect an improvement in overall survival with the addition of adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) to surgery and chemotherapy compared to surgery and chemotherapy alone. SECONDARY...

Splicing deregulation, microRNA and Notch aberrations: fighting the three-headed dog to...
https://doi.org/10.1080/17512433.2022.2074835
Expert Review of Clinical Pharmacology; Anobile DP, Montenovo G et. al.

May 10th, 2022 - Malignant mesothelioma (MMe) is an aggressive rare cancer of the mesothelium, associated with asbestos exposure. MMe is currently an incurable disease at all stages mainly due to resistance to treatments. It is therefore necessary to elucidate key...

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines.
https://doi.org/10.3791/63374
Journal of Visualized Experiments : JoVE; Griffiths TM, Ramos C et. al.

May 10th, 2022 - Current methodologies for the expansion of primary tumor cell lines from rare tumor types are lacking. This protocol describes methods to expand primary tumor cells from surgically resected, malignant pleural mesothelioma (MPM) by providing a comp...

see more →

Guidelines  14 results

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatm...
https://doi.org/10.1016/j.annonc.2021.11.005
Annals of Oncology : Official Journal of the European Soc... Popat S, Baas P et. al.

Dec 4th, 2021 - Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.|2021|Popat S,Baas P,Faivre-Finn C,Girard N,Nicholson AG,|

SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057959
Clinical & Translational Oncology : Official Publication ... Nadal E, Bosch-Barrera J et. al.

Feb 5th, 2021 - Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in ...

Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, trea...
https://doi.org/10.1016/j.ejso.2020.02.011
European Journal of Surgical Oncology : the Journal of Th... Kusamura S, Kepenekian V et. al.

Mar 27th, 2020 - Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.|2020|Kusamura S,Kepenekian V,Villeneuve L,Lurvink RJ,Govaerts K,|diagnosis,pathology,therapy,diagnosis,pathology,therapy,

ERS/EACTS statement on the management of malignant pleural effusions.
https://doi.org/10.1183/13993003.00349-2018
The European Respiratory Journal; Bibby AC, Dorn P et. al.

Jul 29th, 2018 - Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomised clinical trials have been published that have changed the landscape of MPE m...

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clin...
https://doi.org/10.1200/JOP.17.00012
Journal of Oncology Practice; Kindler HL, Ismaila N et. al.

Mar 9th, 2018 - Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary.|2018|Kindler HL,Ismaila N,Hassan R,|diagnosis,therapy,diagnosis,therapy,diagnosis,therapy,

see more →

Drugs  2 results see all →

Clinicaltrials.gov  137 results

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04840615

May 13th, 2022 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04158141

May 13th, 2022 - PRIMARY OBJECTIVE: I. To detect an improvement in overall survival with the addition of adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) to surgery and chemotherapy compared to surgery and chemotherapy alone. SECONDARY...

Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT00715611

May 10th, 2022 - For patients with this type of cancer, the standard of care is treatment with chemotherapy. Radiation therapy is typically not used. This is because radiation to the entire lining of the lung has many side effects that are often severe including d...

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
https://clinicaltrials.gov/ct2/show/NCT04480372

May 5th, 2022 - The trial combines two (Gemcitabine and Atezolizumab). Gemcitabine, alone or in combination regimens is a standard of care for several solid tumors, such as advanced or metastatic NSCLC. It is also used in an off-label setting for pre-treated MPM ...

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT01064648

May 2nd, 2022 - PRIMARY OBJECTIVES: I. To establish the maximum tolerated dose (MTD) and the recommended phase II dose of cediranib maleate (cediranib) in combination with cisplatin and pemetrexed disodium (pemetrexed). (Phase I) II. To assess the safety and toxi...

see more →

News  209 results

SOT101 Plus Pembrolizumab Elicits Encouraging Efficacy in Advanced Solid Tumors
https://www.onclive.com/view/sot101-plus-pembrolizumab-elicits-encouraging-efficacy-in-advanced-solid-tumors

May 2nd, 2022 - The addition of SOT101, an interleukin (IL)-2/IL-15 Rβγ superagonist, to Pembrolizumab (Keytruda) generated a clinical benefit and encouraging safety data in patients with advanced solid tumors, according to data presented at the 2022 AACR Annual ...

Some Reassurance on Neurologic Effects of Checkpoint Inhibitors
https://www.medpagetoday.com/hematologyoncology/othercancers/98373

Apr 22nd, 2022 - Cancer patients treated with immune checkpoint inhibitors (ICIs) had different tradeoffs in neurologic side effects compared with users of other medications, according to a meta-analysis of over three dozen randomized trials. Pooling data from 39 ...

The Most Important Thing About a Master Plan Is Not Having One: Pasi A. Jänne Is a Giant of Cancer Care in Lung Cancer
https://www.onclive.com/view/the-most-important-thing-about-a-master-plan-is-not-having-one-pasi-a-j-nne-is-a-giant-of-cancer-care-in-lung-cancer

Mar 18th, 2022 - As director of 3 centers at Dana-Farber Cancer Institute, a professor of medicine at Harvard Medical School, and head of The Jänne Lab, you might wonder what master plan Pasi A. Jänne, MD, PhD, drafted in his youth to make him so successful. The ...

LiPax Elicits Encouraging RFS Rate in Non–Muscle Invasive Bladder Cancer
https://www.onclive.com/view/lipax-elicits-encouraging-rfs-rate-in-non-muscle-invasive-bladder-cancer

Mar 1st, 2022 - LiPax (TSD-001), a precision-targeted, locally-delivered taxane, was found to induce a recurrence-free survival (RFS) rate of 83% in patients with non–muscle invasive bladder cancer (NMIBC) who had undergone transurethral resection of bladder tumo...

Early Clinical Activity With CDK4/6 Inhibitor in Pretreated Mesothelioma
https://www.medpagetoday.com/hematologyoncology/lungcancer/97252

Feb 17th, 2022 - A drug that made its mark in breast cancer showed preliminary activity in its first-ever clinical trial in mesothelioma. The cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib (Verzenio) achieved disease control at 12 weeks in 14 of 26 patien...

see more →

Patient Education  5 results see all →